The findings show the importance of assessing the histologic grade of gastrointestinal GVHD. No other trials have tested nonpharmacological interventions to improve quality of life in patients with cutaneous GVHD. Oncology nurses must understand these diverse manifestations and their potential impact on patients’ daily lives. Nearly 1 of 5 patients (18%) with cGVHD had kidney dysfunction, with 8% having moderate-severe dysfunction. As a trusted profession, oncology nurses are critical in helping women manage genital cGVHD. Oncology nurses are in a pivotal position to assess for symptoms of female genital cGVHD and to intervene early. Researchers suggest considering multiple factors when seeking a donor for a patient. All patients were adults with a history of allogeneic HSCT diagnosed with chronic, extensive GVHD. Understanding how patients and caregivers describe their health status is crucial to knowing what matters most to patients. Different types of secondary solid tumors can occur after allogeneic HSCT, including oral cancer. The frequency of veno-occlusive disease, hyperacute and acute GVHD, and chronic GVHD were not different between groups. Researchers evaluated two categories of immunosuppressive therapy to evaluate the best approach. It is important to monitor patients who have elevated CMV levels to detect infection and progression early. Results from this meta-review suggest that more prophylactic strategies are needed in the fight against GVHD. Intensive salvage therapy had a 54% complete remission rate whereas non-intensive salvage therapy was lower at 18%. The study used only single-agent tacrolimus for GVHD prophylaxis. Non-relapse mortality was low, and there was good GVHD control with the prophylaxis. Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa. There are 5 criteria that you should discuss with your patients if you suspect frailty. Exercise, diet, and stress reduction can go a long way to improve patient frailty.